Atlas Logo
Parkinson's Progression Markers Initiative - Prodromal Cohort (PPMI - Prodromal PD)
Parkinson's Progression Markers Initiative - Prodromal Cohort logo
BACK
Sample details

The overall aim of PPMI is to identify markers of disease progression to accelerate therapeutic trials and reduce the progression of Parkinson’s Disease (PD) disability. The PPMI Prodromal PD cohort is a part of PPMI Clinical, a study conducting in-person clinical and imaging assessments and biosample collection across 50 international sites. The prodromal cohort includes approximately 1,750 participants at risk of developing PD, as of 2024, with plans to recruit 2,750 participants. This includes those with clinical features or biomarkers of PD, and those with a genetic risk of PD. Baseline assessment began in 2011, and participants are followed up every 6 months for at least 5 years.

Study design
Cohort, Cohort - clinical

Number of participants at first data collection

1,750 (participants, as of 2024)

Recruitment is ongoing

Age at first data collection

≥ 60 years (participants with prodromal symptoms)

≥ 30 years (participants with genetic risk)

Participant year of birth

Varied (participants)

Participant sex
All

Representative sample at baseline?
No

Sample features

Patients and clinical populations
People with mild and major neurocognitive disorders
Dataset details
Loading map...

Countries

Australia, Austria, England, France, Germany

Year of first data collection

2011

Primary Institutions

Institute for Neurodegenerative Disorders (INDD)

University of California, San Francisco (UCSF)

Links

ppmi-info.org/study-design/study-cohorts

clinicaltrials.gov/study/NCT04477785

ppmi-info.org/sites/default/files/docs/PPMI%20Data%20User%20Guide.pdf

neurodegenerationresearch.eu/cohort/parkinson%C2%92s-progression-markers-initiative/

Funders

Michael J. Fox Foundation for Parkinson's Research

Ongoing?
Yes

Data types collected

neuroImagingData
mentalHealthData
Quantitative data collection
  • Interview – face-to-face
  • Interview – phone
  • Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
  • Self-report questionnaire – unspecified
Qualitative data collection
  • None
Neuroimaging data collection
  • Computerized tomography (CT)
  • Diffusion Tensor Imaging (DTI)
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Single-photon emission computed tomography (SPECT)
Linked or secondary data
  • None
Features

Engagement

  • None
  • Keywords

    Disease progression
    Genetics
    Neuroimaging
    Neuropsychiatry
    Neuropsychological testing
    Parkinson's disease (PD)

    Consortia and dataset groups

    Image and Data Archive (IDA)
    Contact us

    |

    FAQS

    |

    Privacy

    |

    © 2024 Louise Arseneault

    Platform by Delosis